ClinicalTrials.gg
CompletedNCT05134012Updated Oct 29, 2026

RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

A Phase 3 interventional study of [O-15]-Water PET Myocardial Perfusion Imaging (MPI) in Coronary Artery Disease, sponsored by MedTrace Pharma A/S. Completed at 13 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by MedTrace Pharma A/S · Phase 3, Interventional, and Diagnostic

How we know

Updated Oct 29, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
232
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,104 studies in Coronary Artery Disease with a site in United States — 99 open to participants now, 144 under way, 10 of them phase 3. Coronary Artery Disease · United States.

Enrollment
253rd of 745
232 · median 107
Started
2022
with 24 others
Phase 3
101 of 1,104
4 open now
Registered
957th of 1,104
by date

Among the 1,104 studies in Coronary Artery Disease with a site in United States, this one is the 253rd largest by enrollment of the 745 interventional ones that give a count, is one of 25 that started in 2022, is one of 101 in phase 3, and was the 957th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

99 of the 1,104 studies in Coronary Artery Disease with a site in United States are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,104 studies in Coronary Artery Disease with a site in United States, or all of them as a file.
02

Study summary

This a Phase 3, prospective, open-label, multicenter study of [15-O]-H2O injection for PET imaging of subjects with suspected CAD. Approximately 182 evaluable participants with suspected CAD referred for testing will be included in the study at approximately 10 study sites in the United States and Europe. Approximately 215 participants will be enrolled to account for an estimated 15% drop-out rate. Screening assessments will occur prior to enrollment to confirm eligibility. All participants will receive two doses of [15-O]-H2O as part of a single PET imaging session (one dose at rest and one during pharmacological stress with adenosine). A safety follow-up phone call will occur 24 ± 8 hrs after completion of the [15-O]-H2O scan.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Myocardial Blood Flow (MBF)
  • Myocardial Perfusion Imaging (MPI)
  • RAPID-WATER-FLOW
  • Positron Emission Tomography (PET)
  • Oxygen-15
  • Coronary Artery Disease (CAD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants ≥18 years;
  2. form (ICF) read, signed, and dated prior to any study procedures being performed;
  3. Participants who fall into any one of the following categories:

    1. Have been referred for an ICA directly of after non-invasive testing (e.g., SPECT or PET MPI, stress echo, CCTA, ETT).
    2. Had an ICA with no intervention. However, if any stenosis >40% but ≤70% was observed, an FFR or iFR assessment was performed.
    3. Had a CCTA with normal coronaries or minimal CAD (no stenosis >25%).

    The SPECT study, PET 15O-H2O study, and ICA or CCTA testing need to be completed within a 30-day window, with time 0 defined as the date of the first of these three tests.

  4. Women of Child Bearing Potential () must be non-pregnant, and non-lactating. For women of childbearing potential, the results of a urine human chorionic gonadotropin (HCG) pregnancy test (with the result known on the day of drug administration) must be negative; these participants must be practicing appropriate from time of the screening visit until the end of the follow-up period. For women who are either surgically sterile (have a documented bilateral tubal ligation or oophorectomy and/or hysterectomy) or are (cessation of menses for more than 1 year), enrollment in the study without a pregnancy test at screening is allowed.
  5. Male will need to use contraceptive methods until end of the follow-up period.
  6. Participants are able to comply with all study procedures as described in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participants are unable to undergo (even partially) any of the imaging procedures;
  2. Participants with a known history of cardiac disease including:

    1. myocardial infarction, previous coronary revascularization, or chronic ischemic cardiomyopathy
    2. primary myocardial disease such as cardiac amyloidosis or hypertrophic cardiomyopathy
    3. known left ventricular dysfunction
    4. moderate or severe aortic or mitral stenosis or regurgitation
  3. Participants in whom adenosine stress testing is , including but not limited to:

    1. Participants with severe or chronic asthma.
    2. Participants with second- or third-degree atrioventricular block without a pacemaker.
  4. Participants with claustrophobia to an extent that would limit their ability to undergo SPECT and PET imaging (patients whose claustrophobia is known to be readily controlled with drugs or psychological support may be enrolled).
  5. Participants who are on sildenafil (Viagra) or oral dipyridamole (Persantine, Aggrenox) therapy or on any PDE5 inhibitor (i.e. tadalafil, avanafil, vardenafil),and for whom its use cannot be terminated or suspended for ≥24 hours prior to treatment of study drug.
  6. Participants with significant co-morbidities that would prevent appropriate completion of the protocol procedures.
  7. Participants who have participated in another research study using drugs within the 30 days prior to enrollment or through the duration of the trial (patients in observational studies with approved agents and participants known to be on placebo may be enrolled).
  8. Participants who have previously participated in this study.
  9. Subjects scheduled for, or planning to undergo, any interventional cardiac procedures between enrollment and ICA (pathway 1) or signing of and 15O-H2O PET MPI (pathway 2 and 3)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
232 participants (actual)

Study arms

  • Experimental
    [O-15]-Water PET Myocardial Perfusion Imaging (MPI)

    All participants with suspected CAD will receive two doses of \[15-O\]-H2O as part of a single PET imaging session (one dose at rest and one during pharmacological stress with adenosine).

    Drug: [O-15]-Water PET Myocardial Perfusion Imaging (MPI)

Interventions

  • Drug[O-15]-Water PET Myocardial Perfusion Imaging (MPI)

    \[15-O\]-H2O injection is a novel PET imaging agent labeled with the radioisotope \[15-O\] administered as an intravenous (IV) injection. Participants will receive \[15-O\]-H2O treatment twice as a part of a single day imaging session. All participants will receive two IV boluses of \[15-O\]-H2O injection in a peripheral vein; one at rest and one during pharmacological stress.

06

What researchers measure

Primary outcomes

  1. Sensitivity and specificity of the [15-O]-H2O PET study using the truth-standard of ICA with FFR/iFR or CCTA.

    Sensitivity and specificity are defined as follows: * True Positives (TP): Subjects with abnormal PET MPI and disease positive by the truth standard * True Negatives (TN): Subjects with normal PET MPI and disease negative by the truth standard * False Positives (FP): Subjects with abnormal PET MPI and disease negative by the truth standard * False Negatives (FN): Subjects with normal PET MPI and disease positive by the truth standard * Sensitivity: TP/(TP + FN) * Specificity: TN/(TN + FP)

    Time frame: 30 days

Secondary outcomes

  1. Sensitivity, specificity, and accuracy of [15-O]-H2O PET MPI in participants of special clinical interest (female, BMI≥30, diabetics, multivessel disease).

    Sensitivity and specificity are defined as follows: * True Positives (TP): Subjects with abnormal PET MPI and disease positive by the truth standard * True Negatives (TN): Subjects with normal PET MPI and disease negative by the truth standard * False Positives (FP): Subjects with abnormal PET MPI and disease negative by the truth standard * False Negatives (FN): Subjects with normal PET MPI and disease positive by the truth standard * Sensitivity: TP/(TP + FN) * Specificity: TN/(TN + FP) * Accuracy: (TN + TP)/(TN + TP + FN + FP)

    Time frame: 30 days

  2. Sensitivity and specificity of 15O-H2O PET in subjects where the standard of truth may use site-determined value of FFR/iFR when the raw FFR/iFR data are not available to the core lab.

    Sensitivity and specificity are defined as follows: * True Positives (TP): Subjects with abnormal PET MPI and disease positive by the truth standard * True Negatives (TN): Subjects with normal PET MPI and disease negative by the truth standard * False Positives (FP): Subjects with abnormal PET MPI and disease negative by the truth standard * False Negatives (FN): Subjects with normal PET MPI and disease positive by the truth standard * Sensitivity: TP/(TP + FN) * Specificity: TN/(TN + FP) * Accuracy: (TN + TP)/(TN + TP + FN + FP)

    Time frame: 30 days

  3. Adverse event analyses will include tabulations of the incidence (number and percent of subjects) with at least one TEAEs overall and by MedDRA system organ class (SOC) and preferred term (PT). This will be repeated for serious adverse.

    Other Safety measures including the following will be summarized descriptively: 1. ECG (ventricular heart rate, PR interval, QRS duration, QT interval, QTc interval) 2. Vital Signs 3. Concomitant Medications 4. Protocol Deviations

    Time frame: 30 days

07

Study locations

13 sites
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University
    St Louis, Missouri 63110, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • University of Virginia Medical Center
    Charlottesville, Virginia 22903, United States
  • University of Ottawa Heart Institute
    Ottawa, Ontario, Canada
  • Aarhus University Hospital
    Aarhus, Denmark
  • University Hospital Freiburg, Clinic for Nuclear Medicine
    Freiburg im Breisgau, Germany
  • Department of Cardiology and Angiology -- Hannover Medical School (MHH)
    Hanover, Germany
  • Amsterdam University Medical Center, Department of Radiology and Nuclear Medicine
    Amsterdam, North Holland 1081HV, Netherlands
  • Sahlgrenska University Hospital
    Gothenburg, Sweden
  • Norrland University Hospital Heart Center
    Umeå, Sweden
08

References and documents

Publications

  • Di Carli MF, Gormsen LC, Chareonthaitawee P, Johnson GB, Beanlands R, DeKemp R, Schindler T, Gropler R, Kulkarni H, McNeely P, Soman P, Oz O, Zaha V, Sorensen J, Harms H, Orlandi C, Vandenbroucke E, Udelson J. Rationale and design of the RAPID-WATER-FLOW trial: Radiolabeled perfusion to identify coronary artery disease using water to evaluate responses of myocardial FLOW. J Nucl Cardiol. 2024 Jan;31:101779. doi: 10.1016/j.nuclcard.2023.101779. Epub 2023 Dec 5. PubMed 38215598 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Oct 2026, 52 months.

Of 30 industry-sponsored phase 3 interventional studies under Coronary Artery Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's 52 months is close to that.

Counting every sponsor, half of 62 studies reached it within 47 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2021
First posted
Nov 24, 2021
StartActual
May 8, 2022
Primary completionActual
Oct 2, 2026
CompletionActual
Oct 2, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 29, 2026
Enrollment
215 (estimated)→232 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Active, not recruiting→Completed
    Enrollment 215 (estimated)→232 (actual)
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05134012
Lead sponsor
MedTrace Pharma A/S
Responsible party
Sponsor
First posted
Nov 24, 2021
Start date
May 8, 2022
Primary completion
Oct 2, 2026
Completion
Oct 2, 2026
Last update
Oct 29, 2026

Study contacts

Nicholas Borys, MD
study director · MedTrace Pharma A/S
Marcelo DiCarli, MD
principal investigator · Brigham and Women's Hospital

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion